E-LIB Suche - Ergebnisse für: Stein, Eytan M.

1

Differentiation syndrome associated with treatment with IDH..:

Montesinos, Pau ; Fathi, Amir T. ; de Botton, Stéphane...
Blood Advances. 8 (2024) 10 - p. 2509-2519 , 2024

Link: https://doi.org/10.1182/..

2

Hypomethylating agents plus venetoclax compared with intens..:

Shimony, Shai ; Bewersdorf, Jan Philipp ; Shallis, Rory M....
Leukemia. 38 (2024) 4 - p. 762-768 , 2024

Link: https://doi.org/10.1038/..

3

Results from phase 1 of the MANIFEST clinical trial to eval..:

Stein, Eytan M. ; Fathi, Amir T. ; Harb, Wael A....
Leukemia & Lymphoma. 65 (2024) 4 - p. 503-510 , 2024

Link: https://doi.org/10.1080/..

4

Interaction between myelodysplasia-related gene mutations a..:

McCarter, Joseph G. W. ; Nemirovsky, David ; Famulare, Christopher A....
Blood Advances. 7 (2023) 17 - p. 5000-5013 , 2023

Link: https://doi.org/10.1182/..

5

Samples from patients with AML show high concordance in det..:

Borate, Uma ; Yang, Fei ; Press, Richard...
Blood Advances. 7 (2023) 20 - p. 6048-6054 , 2023

Link: https://doi.org/10.1182/..

6

MEN1 mutations mediate clinical resistance to menin inhibit..:

Perner, Florian ; Stein, Eytan M. ; Wenge, Daniela V....
Nature. 615 (2023) 7954 - p. 913-919 , 2023

Link: https://doi.org/10.1038/..

7

The menin inhibitor revumenib in KMT2A-rearranged or NPM1-m..:

Issa, Ghayas C. ; Aldoss, Ibrahim ; DiPersio, John...
Nature. 615 (2023) 7954 - p. 920-924 , 2023

Link: https://doi.org/10.1038/..

8

Safety, efficacy, and PK/PD of vorasidenib in previously tr..:

DiNardo, Courtney D. ; De Botton, Stéphane ; Pollyea, Daniel A....
American Journal of Hematology. 98 (2023) 9 - p. , 2023

Link: https://doi.org/10.1002/..

9

Pevonedistat with azacitidine in older patients with TP53-m..:

Saliba, Antoine N. ; Kaufmann, Scott H. ; Stein, Eytan M....
Blood Advances. 7 (2023) 11 - p. 2360-2363 , 2023

Link: https://doi.org/10.1182/..

10

Entospletinib with decitabine in acute myeloid leukemia wit..:

Duong, Vu H. ; Ruppert, Amy S. ; Mims, Alice S....
Cancer. 129 (2023) 15 - p. 2308-2320 , 2023

Link: https://doi.org/10.1002/..

11

Targeting RARA overexpression with tamibarotene, a potent a..:

de Botton, Stéphane ; Cluzeau, Thomas ; Vigil, Carlos...
Blood Advances. 7 (2023) 9 - p. 1858-1870 , 2023

Link: https://doi.org/10.1182/..

12

Use of tamibarotene, a potent and selective RARα agonist, i..:

Stein, Eytan M. ; de Botton, Stephane ; Cluzeau, Thomas...
Leukemia & Lymphoma. 64 (2023) 12 - p. 1992-2001 , 2023

Link: https://doi.org/10.1080/..

13

E7820, an anti-cancer sulfonamide, degrades RBM39 in patien..:

Bewersdorf, Jan Philipp ; Stahl, Maximilian ; Taylor, Justin...
Leukemia. 37 (2023) 12 - p. 2512-2516 , 2023

Link: https://doi.org/10.1038/..

14

Poster: AML-143 Trial in Progress: Phase Ib/II Study of Sir..:

Daver, Naval G. ; Wei, Andrew H. ; Stein, Eytan M....
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S137 , 2022

Link: https://doi.org/10.1016/..

15

AML-432 Overall Survival (OS) by Mutant Allele (R140 or R17..:

DiNardo, Courtney D. ; de Botton, Stéphane ; Risueño, Alberto...
Clinical Lymphoma Myeloma and Leukemia. 22 (2022) - p. S249-S250 , 2022

Link: https://doi.org/10.1016/..